China NMPA Product Recall - Blood flow diversion embolization device

On February 29, 2020, Covidien Medical Devices International Trading (Shanghai) Co., Ltd. announced a voluntary Class II recall of its flow diverting embolization devices. This critical measure was taken due to a significant manufacturing defect: identified weak welding within the products. This flaw presented a potential and serious risk of the device breaking distally during patient use, which could lead to adverse health consequences. The details of this recall were publicly disseminated by the National Medical Products Administration (NMPA), serving as the primary regulatory body overseeing medical product safety in China. Further information regarding the recall was also published on the Shanghai Municipal Drug Administration Website on April 9, 2020. Under this regulatory oversight, Covidien initiated the recall to address the product integrity issue proactively. The required actions involve the immediate voluntary recall of specific models, specifications, and batches of the affected flow diverting embolization devices. Comprehensive information for healthcare providers and stakeholders, including precise product identification details, is provided in the 'Medical Device Recall Event Report Form' to ensure effective management and safeguard patient safety.